The effect of sertraline with or without propranolol on panic attacks in women: a controlled clinical trial.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Sahar Rouhzendeh, Zahra Mousavi, Sepideh Mashayekh-Amiri, Elnaz Shaseb, Seyedeh Tahereh Mirmolaei, Mojgan Mirghafourvand
{"title":"The effect of sertraline with or without propranolol on panic attacks in women: a controlled clinical trial.","authors":"Sahar Rouhzendeh, Zahra Mousavi, Sepideh Mashayekh-Amiri, Elnaz Shaseb, Seyedeh Tahereh Mirmolaei, Mojgan Mirghafourvand","doi":"10.1186/s40780-025-00466-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of propranolol in the treatment of panic attacks has historically been widespread. However, there is insufficient precise evidence regarding the combination of propranolol with sertraline in this context. Panic attacks are a common health issue among women, significantly affecting their personal and social lives. Therefore, this study aimed to determine the effect of sertraline, with or without propranolol, on the severity of panic attack symptoms and depressive symptoms.</p><p><strong>Methods: </strong>This randomized controlled clinical trial included 60 women who attended a specialized university clinic in Tabriz. Participants were randomly assigned to either the sertraline with propranolol group (n = 30) or the sertraline with propranolol placebo group (n = 30) using block randomization method. Both groups received drugs for four weeks. Data were collected using the Panic Disorder Severity Scale- Self-Report (PDSS-SR) and the Beck Depression Inventory-Short Form (BDI-13). The Mann-Whitney U test was employed to compare outcomes between the two groups, and Wilcoxon tests were used for within-group comparisons.</p><p><strong>Results: </strong>Samples were enrolled from July 22, 2024, to February 11, 2025. The two groups exhibited no statistically significant differences in sociodemographic characteristics (p > 0.05). After the intervention, the mean score for the severity of panic attack symptoms in the sertraline with propranolol group was 6.6 (SD: 4.4), compared to 13.1 (SD: 5.4) in the sertraline with propranolol placebo group, indicating a statistically significant difference (P < 0.001). Additionally, the mean (SD) post-intervention depression score was 8.9 (4.8) in the sertraline with propranolol group and 15.5 (7.2) in the sertraline with propranolol placebo group, with the sertraline with propranolol group demonstrating a significantly lower mean depression score according to the Mann-Whitney U test (p = 0.001). Within-group comparisons also revealed a significant reduction in the severity scores for both panic attack symptoms and depression in the sertraline with propranolol group (P < 0.001).</p><p><strong>Conclusion: </strong>Based on the results of this trial, using propranolol alongside sertraline reduces the severity of panic attacks. Given these promising results, further studies in various settings are recommended to provide high-certainty evidence in this field.</p><p><strong>Trial registration: </strong>Iranian Registry of Clinical Trials (IRCT): IRCT20120718010324N70. Date of registration: 2022-08-31; URL: https://irct.behdasht.gov.ir/user/trial/65033/view .</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"57"},"PeriodicalIF":1.2000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228203/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Health Care and Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40780-025-00466-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The use of propranolol in the treatment of panic attacks has historically been widespread. However, there is insufficient precise evidence regarding the combination of propranolol with sertraline in this context. Panic attacks are a common health issue among women, significantly affecting their personal and social lives. Therefore, this study aimed to determine the effect of sertraline, with or without propranolol, on the severity of panic attack symptoms and depressive symptoms.

Methods: This randomized controlled clinical trial included 60 women who attended a specialized university clinic in Tabriz. Participants were randomly assigned to either the sertraline with propranolol group (n = 30) or the sertraline with propranolol placebo group (n = 30) using block randomization method. Both groups received drugs for four weeks. Data were collected using the Panic Disorder Severity Scale- Self-Report (PDSS-SR) and the Beck Depression Inventory-Short Form (BDI-13). The Mann-Whitney U test was employed to compare outcomes between the two groups, and Wilcoxon tests were used for within-group comparisons.

Results: Samples were enrolled from July 22, 2024, to February 11, 2025. The two groups exhibited no statistically significant differences in sociodemographic characteristics (p > 0.05). After the intervention, the mean score for the severity of panic attack symptoms in the sertraline with propranolol group was 6.6 (SD: 4.4), compared to 13.1 (SD: 5.4) in the sertraline with propranolol placebo group, indicating a statistically significant difference (P < 0.001). Additionally, the mean (SD) post-intervention depression score was 8.9 (4.8) in the sertraline with propranolol group and 15.5 (7.2) in the sertraline with propranolol placebo group, with the sertraline with propranolol group demonstrating a significantly lower mean depression score according to the Mann-Whitney U test (p = 0.001). Within-group comparisons also revealed a significant reduction in the severity scores for both panic attack symptoms and depression in the sertraline with propranolol group (P < 0.001).

Conclusion: Based on the results of this trial, using propranolol alongside sertraline reduces the severity of panic attacks. Given these promising results, further studies in various settings are recommended to provide high-certainty evidence in this field.

Trial registration: Iranian Registry of Clinical Trials (IRCT): IRCT20120718010324N70. Date of registration: 2022-08-31; URL: https://irct.behdasht.gov.ir/user/trial/65033/view .

舍曲林加或不加心得安对女性惊恐发作的影响:一项对照临床试验。
背景:使用心得安治疗惊恐发作在历史上是广泛的。然而,在这种情况下,关于心得安与舍曲林联合使用的确切证据不足。惊恐发作是妇女常见的健康问题,严重影响她们的个人和社会生活。因此,本研究旨在确定舍曲林联合或不联合心得安对惊恐发作症状和抑郁症状严重程度的影响。方法:这项随机对照临床试验包括60名妇女,她们在大不里士的一所大学专科诊所就诊。采用分组随机法,将参与者随机分为舍曲林加心得安组(n = 30)和舍曲林加心得安安慰剂组(n = 30)。两组都接受了为期四周的药物治疗。使用惊恐障碍严重程度量表-自我报告(PDSS-SR)和贝克抑郁量表-短表(BDI-13)收集数据。两组间比较采用Mann-Whitney U检验,组内比较采用Wilcoxon检验。结果:样本入组时间为2024年7月22日至2025年2月11日。两组的社会人口学特征差异无统计学意义(p < 0.05)。干预后,舍曲林联合心得安组惊恐发作症状严重程度平均得分为6.6分(SD: 4.4),舍曲林联合心得安安慰剂组平均得分为13.1分(SD: 5.4),差异有统计学意义(P)。结论:根据本试验结果,舍曲林联合心得安可降低惊恐发作严重程度。鉴于这些有希望的结果,建议在各种情况下进行进一步的研究,以在该领域提供高确定性的证据。试验注册:伊朗临床试验注册中心(IRCT): IRCT20120718010324N70。注册日期:2022-08-31;网址:https://irct.behdasht.gov.ir/user/trial/65033/view。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
29
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信